BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, May 4, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 26, 2007
View Archived Issues
Positive 'Restless Legs' Data Send XenoPort Shares Soaring
Shares of XenoPort Inc. leaped 44 percent on news that its gabapentin prodrug, XP13512, met its endpoints in the first of three Phase III studies in restless legs syndrome (RLS). (BioWorld Today)
Read More
First Phase III Data Positive With BDSI's Buccal Fentanyl
Read More
Cytos, Novartis Enter Potential $500M Deal On Nicotine Vaccine
Read More
Genzyme Grows Markets, Beats 1st Quarter Estimates
Read More
Poniard's Public Offering Brings In $65M, Mainly For Picoplatin
Read More
Other News To Note
Read More
Appointments And Advancements
Read More
Clinic Roundup
Read More